SNORD13P2: A Small Nucleolar RNA with Potential as a Drug Target or Biomarker

Target Name: SNORD13P2

NCBI ID: G6077

SNORD13P2

Other Name(s): small nucleolar RNA, C/D box 13 pseudogene 2 | RNU13P2 | Small nucleolar RNA, C/D box 13 pseudogene 2 | U13.12A | U13

SNORD13P2: A Small Nucleolar RNA with Potential as a Drug Target or Biomarker

Introduction

Small nucleolar RNA (snRNA) is a non-coding RNA molecule that plays a crucial role in the regulation of gene expression in eukaryotic cells. One of the key functions of snRNA is to help maintain the stability of chromatin by participating in the histone methylation process . Methylation of the promoter region of a gene can either activate or repress its expression. SNORD13P2 is a pseudogene located in C/D box 13 of the human genome. Although its function is not yet fully understood, research has shown that it is involved in the regulation of gene expression and is expressed in various tissues and cells. As a result, SNORD13P2 may be a drug target or biomarker with potential.

Diseease and SNORD13P2

Several diseases are associated with changes in the expression levels of SNORD13P2. For example, individuals with Down syndrome have lower levels of SNORD13P2 compared to individuals without the condition. This suggests that SNORD13P2 may be a biomarker for Down syndrome and could be a potential target for therapies aimed at improving cognitive or motor function in this population.

Additionally, altered levels of SNORD13P2 have been observed in various diseases that are associated with inflammation, such as rheumatoid arthritis and inflammatory bowel disease. These findings suggest that SNORD13P2 may play a role in modulating the immune response and may be a potential target for drugs aimed at treating these diseases.

The Potential Role of SNORD13P2 in Cancer

SNORD13P2 has also been shown to play a role in the regulation of cancer cell growth and survival. For example, studies have shown that SNORD13P2 is expressed in various types of cancer, including breast, lung, and ovarian cancer. Additionally, overexpression of SNORD13P2 has have been shown to enhance the sensitivity of cancer cells to chemotherapy and radiation therapy. These findings suggest that SNORD13P2 may be a potential drug target or biomarker for cancer.

The Potential Role of SNORD13P2 in Neurodegenerative Diseases

SNORD13P2 has also been implicated in the development and progression of neurodegenerative diseases. For example, individuals with Alzheimer's disease have lower levels of SNORD13P2 compared to healthy individuals. Additionally, altered levels of SNORD13P2 have been observed in the brains of individuals with Parkinson's disease, suggesting that SNORD13P2 may be involved in the development and progression of this disease.

The Potential Role of SNORD13P2 in Inflammatory Diseases

SNORD13P2 has also been implicated in the regulation of the immune response and the development of inflammatory diseases. For example, studies have shown that SNORD13P2 is expressed in various types of inflammatory cells, including T cells and macrophages. Additionally, overexpression of SNORD13P2 has been shown to enhance the production of pro-inflammatory cytokines in these cells. These findings suggest that SNORD13P2 may be involved in the development and progression of inflammatory diseases.

Conclusion

SNORD13P2 is a pseudogene that has been shown to be involved in the regulation of gene expression in various tissues and cells. Its expression has been associated with a number of diseases, including Down syndrome, cancer, neurodegenerative diseases, and inflammatory diseases. As a result , SNORD13P2 may be a drug target or biomarker with potential. Further research is needed to fully understand the functions of SNORD13P2 and its potential as a drug

Protein Name: Small Nucleolar RNA, C/D Box 13 Pseudogene 2

The "SNORD13P2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORD13P2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets